Join

Compare · MOH vs THMO

MOH vs THMO

Side-by-side comparison of Molina Healthcare Inc (MOH) and ThermoGenesis Holdings Inc. (THMO): market cap, price performance, sector, and recent activity on the wire.

Summary

  • MOH operates in Health Care, while THMO operates in Industrials - the two are in different parts of the market.
  • MOH is the larger of the two at $16.65B, about 1684.1x THMO ($9.9M).
  • Over the past year, MOH is down 45.1% and THMO is up 0.0% - THMO leads by 45.1 points.
  • MOH has hit the wire 3 times in the past 4 weeks while THMO has been quiet.
  • MOH has more recent analyst coverage (25 ratings vs 0 for THMO).
PerformanceMOH+20.40%THMO+0.00%
2026-03-09+0.00%2026-04-24
MetricMOHTHMO
Company
Molina Healthcare Inc
ThermoGenesis Holdings Inc.
Price
$175.91+0.84%
$0.32-11.52%
Market cap
$16.65B
$9.9M
1M return
+25.82%
+0.00%
1Y return
-45.10%
+0.00%
Industry
Medical Specialities
Medical Specialities
Exchange
NYSE
NASDAQ
IPO
2003
News (4w)
3
0
Recent ratings
25
0
MOH

Molina Healthcare Inc

Molina Healthcare, Inc. provides managed health care services to low-income families and individuals under the Medicaid and Medicare programs and through the state insurance marketplaces. The company operates in two segments, Health Plans and Other. As of December 31, 2020, it served approximately 4.0 million members eligible for Medicaid, Medicare, and other government-sponsored healthcare programs in 15 states. The company offers its health care services for its members through contracts with a network of providers, including independent physicians and physician groups, hospitals, ancillary providers, and pharmacies. Molina Healthcare, Inc. was founded in 1980 and is headquartered in Long Beach, California.

THMO

ThermoGenesis Holdings Inc.

ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company manufactures and markets AXP II Automated Cell Separation System, an automated cell separation system for isolating and retrieving stem, and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing, and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. It offers PXP Point-of-Care System, an automated sterile system for the automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; PXP-LAVARE System, an automated system designed to wash, re-suspend, and volume reduce cell suspensions; PXP-1000 System, an automated system for fast and reproducible separation of multiple cellular components from blood with minimal red blood cell contamination; and X-Series products, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, X-Mini for small scale cell purification, and X-BACS System under development for large scale cell purification. It also provides CAR-TXpress Platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing, and controls needs. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California.

Latest MOH

Latest THMO